Filing identity and reporting period
The supplied filing is Cyclacel Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2013—not a filing for Bio Green Med Solution, Inc. The company describes itself as a development-stage biopharmaceutical business focused principally on cancer drug candidate sapacitabine.
Financial performance and position
Amounts below are in U.S. dollars; financial statement figures are in millions unless stated otherwise.
- Revenue: Third-quarter revenue was $0.309 million, all from grants, versus $0.038 million a year earlier. Nine-month revenue was $0.785 million versus $0.064 million. There was no collaboration or R&D revenue in either 2013 period.
- Expenses and losses: Third-quarter R&D expense rose to $4.575 million from $1.532 million, mainly due to SEAMLESS Phase 3 trial and capsule-manufacturing costs. G&A declined to $1.529 million from $2.028 million. Operating loss was $5.795 million versus $3.522 million; net loss was $5.004 million versus $1.890 million. Nine-month operating loss was $14.000 million versus $10.449 million; net loss narrowed to $6.594 million from $8.422 million, aided substantially by a one-time patent-sale gain.
- Per-share results: Basic and diluted net loss applicable to common shareholders was $0.32 for the quarter versus $0.25, and $1.15 for nine months versus $1.09. Nine-month 2013 results include a $9.027 million deemed dividend related to preferred-stock exchanges.
- Cash flow: Nine-month operating cash use was $12.821 million versus $9.584 million. Investing activities provided $5.665 million, including $5.5 million from the Celgene patent sale. Financing activities provided $25.381 million, principally from a May equity offering and Aspire share sales. Cash increased $18.075 million to $34.487 million.
- Liquidity and balance sheet: At September 30, cash and cash equivalents were $34.487 million, working capital was $28.741 million, total assets were $37.989 million, and total liabilities were $8.978 million. The filing reports no conventional borrowings outstanding. Accumulated development-stage deficit was $285.871 million.
- Margins: Conventional gross and operating margins are not meaningful for this development-stage company, which had no continuing product sales and minimal grant revenue relative to R&D spending.
Material changes and unusual items
- The company sold four romidepsin-related patents to Celgene for $5.5 million in April 2013, ending related litigation. The $5.5 million was recorded in other income and materially improved nine-month results; it is non-recurring.
- In May 2013, the company sold 6,833,334 common shares at $3.00 per share, receiving approximately $19.0 million net. It also raised $6.6 million from Aspire under an earlier share-purchase arrangement during the first nine months.
- During the first nine months, 877,869 preferred shares were exchanged for 1,684,471 common shares, including incremental shares beyond the stated conversion terms. This generated a $9.027 million deemed dividend and diluted common shareholders.
- Product distribution operations for ALIGN products had ceased effective September 30, 2012 and are reported as discontinued operations. Nine-month 2013 discontinued-operations income was $0.042 million, compared with $0.904 million in 2012.
- There were no significant changes in reported fair-value liabilities during the quarter; the Economic Rights obligation was settled in April 2013. A potential Scottish Enterprise payment of up to approximately £4 million (about $6.2 million) is contingent on Scottish staffing levels and was valued at only $0.020 million.
Outlook, risks, and contingencies
- Management expected existing resources to fund planned operations for at least 12 months and beyond completion of the SEAMLESS Phase 3 trial, but not to complete development of other indications or candidates or to commercialize products. The company expects continued substantial losses and increased 2013 R&D spending as SEAMLESS enrollment and grant-supported work progress.
- Development priorities center on sapacitabine, including the SEAMLESS Phase 3 trial for elderly AML patients. The FDA Special Protocol Assessment does not guarantee approval. Other programs include seliciclib and earlier-stage candidates; further development depends on resources and may involve partnerships.
- On November 14, 2013, after quarter-end, the company entered a new Aspire agreement: Aspire initially purchased 511,509 shares for $2.0 million and committed to purchase up to an additional $18.0 million over two years, subject to agreement terms and share registration. The facility may cause dilution; the company controls the timing and amount of sales.
- Major risks include clinical-trial delay or failure, adverse events, regulatory uncertainty, dependence on third-party research and manufacturing, competition, intellectual-property challenges, and inability to obtain additional capital on acceptable terms. If funding is insufficient, trials or R&D programs could be delayed, reduced, or terminated.
- Preferred stock carries a 6% cumulative dividend and approximately $4.0 million aggregate liquidation preference at quarter-end. The board declared a $0.15-per-share quarterly dividend in September, paid November 1, 2013. Future dividends depend on legal and financial capacity and board decisions.
Most important facts for investors to verify
- Confirm the issuer: the supplied text is Cyclacel Pharmaceuticals, Inc., despite the request metadata naming Bio Green Med Solution, Inc.
- Check subsequent clinical and regulatory developments for sapacitabine and the SEAMLESS trial; the filing provides no clinical outcome update establishing efficacy or approval.
- Assess cash runway against ongoing operating cash use and planned trial spending; the 12-month liquidity statement is management’s estimate, not a guarantee.
- Review the terms, registration status, share limits, and actual usage of the November 2013 Aspire financing facility, including potential dilution.
- Separate recurring operating performance from the Celgene patent-sale gain and account for preferred-stock exchange dilution and dividends.